semaglutide auburn ⏺Type 2 diabetes mellitus 🔵 (tablet) Initial, 3 mg orally once daily for 30 days, then ⤴️increase dose to 7 mg once daily; dose may be ⤴️increased to 14 mg once Exciting news! 🎉 Auburn MedAesthetics

Early research shows GLP-1 analogs may help improve psoriasis in people with type 2 diabetes

Patients and clinicians are encouraged to: Report any new neurological or haematological symptoms promptly to a GP, and seek urgent assessment if neurological symptoms are present Discuss nutritional supplementation as part of the initial treatment consultation Refer to a dietitian where dietary intake is significantly restricted or where multiple deficiencies are identified Report suspected adverse drug reactions including any nutritional concerns potentially related to retatrutide via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk) Stay informed as MHRA and NICE guidance evolves following any future licensing decision for retatrutide Proactive nutritional monitoring is a cornerstone of safe, responsible prescribing for any medicine that substantially alters dietary behaviour, and retatrutide should be no exception

Spending on GLP-1 drugs for currently covered indications such as type 2 diabetes under Medicare and Medicaid has increased substantially in a relatively short period of time

This is a common practice among research peptide vendors, though researchers accustomed to transparent pricing from companies like Peptide Sciences may find it inconvenient